当前位置：   首页 > 需求大厅

 >  生产研发 

控释衣膜溶液中的丙酮回收装置： 我公司生产生产的参透泵控释片多以醋酸纤维素为控释衣膜，醋酸纤维素的包衣溶液是丙酮，丙酮的沸点较低，在包衣的过程丙酮挥发难以回收。请设计并提供套生产可行的丙酮回收装置。   [更多]

寻找一种载体某些细胞或分子如蛋白质，DNA，RNA，和microRNA，用这些载体来制备高选择性的靶向药物，给药的方法是让药物化合物给药和输送到身体的病灶而达到治疗效果。具体的要求请看下面链接：https://www.innocentive.com/ar/challenge/9933675 AWARD: $30,000 USD | DEADLINE: 2/17/15 | ACTIVE SOLVERS: 108 | POSTED: 1/16/15 Exosomes are membrane-bound vesicles that are produced by many, if not all cell types. Exosomes are able to selectively target certain cells and deliver molecules such as proteins, DNA, RNA, and microRNA. These vesicles are thought to have great potential for targeted drug delivery. The Seeker desires innovative methods for exosome drug loading without significant disruption of the membrane components and properties of the exosome. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933675 Challenge Overview Drug delivery is the method by which pharmaceutical compounds are administered and transported in the body to achieve therapeutic efficacy. Recently, exosomes have been identified as a novel method to deliver drugs in a targeted manner and their potential is derived from natural components such as specific proteins/lipids contained in the membrane of exosomes. Successful delivery of substantial amounts of therapeutic drugs using exosomes is critically dependent on a highly efficient and broadly applicable methodology for loading exosomes with the therapeutic agent, however at present no such technology is available. The Seeker is looking for one or more technologies that will facilitate exosome drug loading without significant disruption of the membrane components and properties of the exosome.   [更多]

静脉注射的优点就是快速静脉注射药物的分布在整个身体。通常,这些药物总是快速代谢，快速排出，导致短期的临床疗效。大家可以从微丸持续释放显效得皮启发。具体看链接：https://www.innocentive.com/ar/challenge/9933723 Intravenous delivery allows for the rapid distribution of injected drugs from the veins throughout the entire body. Oftentimes, these drugs are quickly metabolized and excreted resulting in short durations of clinical efficacy. Certain therapies may benefit from a bolus followed by sustained release. The Seeker wishes to identify a technology to sustain the delivery of a human high dose intravenous drug from a single injection administered over a period of 15 to 30 minutes. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933723 Challenge Overview An intravenous sustained drug delivery technology is desired for a high dose drug that needs to be delivered over 8 to 10 hours. This intravenous sustained release delivery technology would allow a bolus of drug (approximately 40 to 60%) to be delivered quickly upon intravenous administration followed by the remaining dose (60 to 40%) delivered in a near zero order fashion from this intravenous administration over an 8 to 10 hour interval. This drug delivery technology needs to use materials that are already recognized as safe or can be easily qualified for parenteral administration in humans. This drug delivery technology should present no encumbrance to nurses administering the drug in a hospital setting. This technology should be amenable to delivering about 2 grams of a drug with an aqueous solubility of approximately 0.75 grams in 50 mL at 25°C and approximately 1 gram in 50 mL at 37°C during the 8 to 10 hour interval. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on March 21, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the   [更多]

单人中标 赏金分配： $ 30,000 截止日期：2015年1月5日 已有提案：104件 发布时间：14年11月3日 已选0个，还需要1个。 具体要求：研究人员需要一种理论和数学模型来描述已知药物分子和药物性质来预测在水溶媒中药片的溶出过程。这一悬赏只需要一个书面建议。 以下几条信息必须同时满足: 1. 必须在2015年1月5日下午11时59分（美国东部时间）收到，逾期的投标概不受理。只需要提案人一个书面建议提交。解决方领取奖金的同时，必须将其独有的知识产权（IP）的权利转让给举办方。 2.这个悬赏任务是必须寻找一种理论和数学模型来描述已知药物分子和药物性质来预测在水溶媒中药片的溶出过程。而这种药物的晶形、分子结构、活性和非活性成份的重量比、粒径、水溶液的PH等等都是已知并且固定的。 3、投稿在此网站：Multi-Scale Modeling of Tablet Dissolution | InnoCentive Challenge https://www.innocentive.com/ar/challenge/9933558   [更多]

本公司需要拉米夫定和齐多夫定的大生产工艺，有意向者请联系   [更多]

　　要求 　　1.不得侵犯他人专利，如有侵犯，提供者承担损失 　　2.要求有详细技术参数，不能只是一个合成路线 　　3.要求生产路线，成品率不得比现有公开合成方法低 　　4.要求为中试生产工艺   [更多]

基因治疗的概念出现在几十年前,当研究人员推测,人类疾病可以通过精确使用一种技术引入外来DNA来解决遗传缺陷和疾病症状。近年来，基因治疗的进步已经涉足治疗遗传疾病，癌症，神经退行性疾病等各领域。遗传性疾病如色素性视网膜炎等少数眼部疾病的基因也可以如此治疗。公司征集一种在人类眼部组织定性和定量(半)测量体内基因表达的方法。 具体如下https://www.innocentive.com/ar/challenge/9933643 The concept of gene therapy arose decades ago, when researchers postulated that human diseases could be treated by using a technique to introduce foreign DNA to correct genetic defects and disease phenotypes. In recent years, advances in gene therapy have been documented in the treatment of genetic disorders, cancer, and neurodegenerative diseases. Inherited diseases such as retinitis pigmentosa are among a handful of ocular diseases that are amenable to gene therapy. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933643 Challenge Overview The number of clinical trials for gene therapy to treat ocular disorders is on the rise. Inherited diseases such as retinitis pigmentosa among others are thought to be good candidates for targeted treatment. Currently, there is no method in humans to determine the level or geographic location of transgene expression following administration of gene therapy for diseases of the eye, specifically the retina. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 20, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a   [更多]

　　富马酸酮替芬原料工艺，要求工艺成熟，标准EP   [更多]

求五水头孢唑林钠原料药合成工艺，有的请回复！   [更多]

肝脏疾病是一种由病毒或有毒物连续侵害造成肝脏晚期纤维化的慢性疾病。目前，我们的治疗方法很有限，寻找治疗方法的大多数临床试验都失败了，部分原因是由于缺乏预测肝脏疾病发展的生物标志物。公司需要寻找一种新的生物标志物，对提高疾病的可控性会有很大的帮助，定期监测生物标志物也可以促进临床试验治疗药物的进一步发展。 具体可以查看https://www.innocentive.com/ar/challenge/9933671 Challenge Overview Liver disease represents a worldwide unmet medical need. Although there are various causes, the danger is that the liver will become so damaged that it can no longer function adequately. Whether the insult is a viral infection, chemical injury, or immune-related, liver disease follows a slow and steady progression. Early stage liver disease is characterized by inflammation, which if left untreated, can cause scarring and fibrosis. A healthy liver is capable of repair and regeneration, but when there are architectural changes to the tissue, the damage can no longer be reversed. Biopsies are routinely conducted to diagnose liver fibrosis and cirrhosis. Undergoing this invasive procedure involves significant abdominal pain along with the risk for complications and sampling error. Therefore, many patients are reluctant to have a second biopsy even when it is medically advisable. The Seeker desires a specific and sensitive biomarker(s) that is highly associated with liver fibrosis and could be used as a surrogate for clinical efficacy and ideally, could guide treatment selection. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 17, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, as further described in the Challenge-Specific Agreement, Solvers will grant to the Seeker a one hundred and eighty (180)-day Exclusivity Period from the deadline [11:59 PM (US Eastern Time) on August 17, 2015] for a non-exclusive   [更多]